POAI
Predictive Oncology Inc.
Medical - Instruments & Supplies
Market Cap$27M
5Y Perf.-98.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
POAI vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-56.9%
POAI vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | POAI | DBVT |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Biotechnology |
| Market Cap | $27M | $1712.35T |
| Revenue (TTM) | $728K | $0.00 |
| Net Income (TTM) | $-84M | $-168M |
| Gross Margin | 50.2% | — |
| Operating Margin | -14.2% | — |
| Total Debt | $2M | $22M |
| Cash & Equiv. | $735K | $194M |
POAI vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
POAI
DBVT
| Stock | May 20 | Apr 26 | Return |
|---|---|---|---|
| Predictive Oncology… (POAI) | 100 | 1.1 | -98.9% |
| DBV Technologies S.… (DBVT) | 100 | 43.1 | -56.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: POAI vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DBVT leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Predictive Oncology Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
POAI
Predictive Oncology Inc.
The Growth Play
POAI is the clearest fit if your priority is growth exposure.
- Rev growth -0.2%, EPS growth 35.6%, 3Y rev CAGR 4.6%
- -0.2% revenue growth vs DBVT's -100.0%
Best for: growth exposure
DBVT
DBV Technologies S.A.
The Income Pick
DBVT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 1.26
- -87.0% 10Y total return vs POAI's -100.0%
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | POAI | -0.2% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs POAI's -115.8% |
| Stability / Safety | DBVT | Beta 1.26 vs POAI's 1.55 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs POAI's -67.6% |
| Efficiency (ROA) | DBVT | -89.0% ROA vs POAI's -26.9% |
POAI vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
POAI vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDBVTLAGGINGPOAI
POAIPredictive Oncology I…
1leads
DBVTDBV Technologies S.A.
4leads
6 Total Categories
CATEGORYLEADERvs POAIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
POAI1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DBVT5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT6/6
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
POAI and DBVT operate at a comparable scale, with $728,195 and $0 in trailing revenue.
| Metric | POAIPredictive Oncolo… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $728,195 | $0 |
| EBITDAEarnings before interest/tax | -$9M | -$112M |
| Net IncomeAfter-tax profit | -$84M | -$168M |
| Free Cash FlowCash after capex | -$9M | -$151M |
| Gross MarginGross profit ÷ Revenue | +50.2% | — |
| Operating MarginEBIT ÷ Revenue | -14.2% | — |
| Net MarginNet income ÷ Revenue | -115.8% | — |
| FCF MarginFCF ÷ Revenue | -12.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -99.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -220.6% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
POAI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | POAIPredictive Oncolo… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $27M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $28M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -2.19x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 16.49x | — |
| Price / BookPrice ÷ Book value/share | — | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
POAI leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
DBVT leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
DBVT delivers a -130.2% return on equity — every $100 of shareholder capital generates $-130 in annual profit, vs $-3 for POAI. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs POAI's 2/9, reflecting mixed financial health.
| Metric | POAIPredictive Oncolo… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -3.0% | -130.2% |
| ROA (TTM)Return on assets | -26.9% | -89.0% |
| ROICReturn on invested capital | -4.7% | — |
| ROCEReturn on capital employed | -184.7% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | $1M | -$172M |
| Cash & Equiv.Liquid assets | $734,673 | $194M |
| Total DebtShort + long-term debt | $2M | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
DBVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $160 for POAI. Over the past 12 months, DBVT leads with a +110.4% total return vs POAI's -67.6%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs POAI's -55.0% — a key indicator of consistent wealth creation.
| Metric | POAIPredictive Oncolo… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -30.7% | +4.9% |
| 1-Year ReturnPast 12 months | -67.6% | +110.4% |
| 3-Year ReturnCumulative with dividends | -90.9% | +19.7% |
| 5-Year ReturnCumulative with dividends | -98.4% | -69.1% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -55.0% | +6.2% |
DBVT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than POAI's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs POAI's 15.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | POAIPredictive Oncolo… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.55x | 1.26x |
| 52-Week HighHighest price in past year | $32.10 | $26.18 |
| 52-Week LowLowest price in past year | $1.03 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +15.3% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 65.7 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 505K | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | POAIPredictive Oncolo… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). POAI leads in 1 (Valuation Metrics).
Best OverallDBV Technologies S.A. (DBVT)Leads 4 of 6 categories
Loading custom metrics...
POAI vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is POAI or DBVT a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — POAI or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -98. 4% for Predictive Oncology Inc. (POAI). Over 10 years, the gap is even starker: DBVT returned -87. 0% versus POAI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — POAI or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Predictive Oncology Inc. 's 1. 55β — meaning POAI is approximately 23% more volatile than DBVT relative to the S&P 500.
04Which is growing faster — POAI or DBVT?
On earnings-per-share growth, the picture is similar: Predictive Oncology Inc.
grew EPS 35. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — POAI or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -751. 4% for Predictive Oncology Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -673. 7% for POAI. At the gross margin level — before operating expenses — POAI leads at 49. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — POAI or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is POAI or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Predictive Oncology Inc. (POAI) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, POAI: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between POAI and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.